Asia Pacific Sleep Apnea Diagnostics Market is expected to reach US$ 162.98 million by 2028

Finger Tip Oximeter Segment to dominate Asia Pacific Sleep Apnea Diagnostics Market during 2021–2028 

According to a new market research study on “Asia Pacific Sleep Apnea Diagnostics Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product and End User,” is expected to reach US$ 162.98 million by 2028 from US$ 106.92 million in 2021. The market is estimated to grow at a CAGR of 6.2% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific sleep apnea diagnostics market along with the drivers and restraints pertaining to the market growth. Fostering prevalence of sleep apnea, boosting scope of telemedicine, and increasing rising geriatric population are the major factor driving the growth of the Asia Pacific sleep apnea diagnostics market. However, high charges of diagnosis of sleep apnea hinder the growth of Asia Pacific sleep apnea diagnostics market. 

A link between OSA and COVID-19 severity has been proposed based on parallels in pathophysiology and mutually promoting pathways that promote both infection risk and immune response to the virus. 8 OSA causes a cascade of persistent low-grade systemic inflammatory processes including oxidative stress as a result of increased creation and propagation of reactive oxygen species. The researchers looked at 4,668 patients with COVID-19, 443 of whom also had obstructive sleep apnea (OSA). Obstructive sleep apnea (OSA) was associated with a greater risk of overall mortality, both before any adjustment and after adjusting for demographics. Covid-19 has shown, as a chest specialist that it is one of the independent predictors of development of severe Covid pneumonia. Because any severe sleep apnea patient will have a very bad upper airway tone. There are many patients getting pneumonia in Covid-19, landing up in the ICU, just because they had sleep apnea and which was not treated. Covid-19 also has shown us that patient they have come with problem like snoring because many people started having psychological dyspnea, dyspnea means uncomfortable awareness of one's own breathing. There are more patients asking for getting themselves tested for sleep study. That's the new change which can be seen as clinicians. Changes imposed due to the pandemic have led to a surge in individuals reporting sleep problems. The findings raise the need to screen for worsening sleep patterns and use of sleeping aids, especially in more susceptible populations, namely, women and people with insecure livelihoods subjected to social isolation. With telehealth on the rise, those surveyed in Asia Pacific are open to online means to address sleep-related concerns, yet fear hinders many from getting tested for obstructive sleep apnea. The patient population and disease burden of sleep-disordered breathing (SDB), insomnia, and other sleeping disorders are quite high in China.

The Asia Pacific sleep apnea diagnostics market is segmented on the basis of product, end user, and country. Based on product, the market is segmented into polysomnography (PSG) device, home sleep testing devices, oximeter, actigraphy monitoring device, and sleep apnea screening device. In 2021, polysomnography (PSG) device segment held the largest share in the market, and oximeter is expected to be the fastest growing segment during the forecast period. Further based on oximeter, the market is segmented into finger tip oximeter, handheld oximeter, wrist-worn oximeter, and tabletop oximeter. In 2021, finger tip oximeter segment held the largest share in the market, and it is also expected to be the fastest growing segment during the forecast period. Based on end user, the market is bifurcated into hospitals and sleep laboratories and home care settings. In 2021, hospitals and sleep laboratories segment held the largest share in the market, and home care settings is expected to be the fastest growing segment during the forecast period. Similarly Based on country the market is segmented into China, Japan, India, South Korea, Australia, and Rest of Asia Pacific. In 2021, China held the largest share in the market, and it is also expected to be the fastest growing country during the forecast period.

ResMed, Inc.; Nihon Kohden Corporation LLC; SOMNOmedics GmbH; Cleveland Medical Devices Inc.; Koninklijke Philips N.V.; Natus Medical Incorporated; Itamar Medical Ltd.; Compumedics Limited; and Drive DeVilbiss International are among the leading companies in the Asia Pacific sleep apnea diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com